Rabbit Recombinant Monoclonal CD7 antibody - conjugated to PE.
IgG
Rabbit
PE
Ex: 480;565nm, Em: 578nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Liquid
Monoclonal
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Select an associated product type
T-cell antigen CD7, GP40, T-cell leukemia antigen, T-cell surface antigen Leu-9, TP41, CD7
Rabbit Recombinant Monoclonal CD7 antibody - conjugated to PE.
T-cell antigen CD7, GP40, T-cell leukemia antigen, T-cell surface antigen Leu-9, TP41, CD7
IgG
Rabbit
PE
Ex: 480;565nm, Em: 578nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Liquid
Monoclonal
EPR4242
Affinity purification Protein A
The mouse and rat recommendation is based on theIHC-Presults. We do not guarantee WB for mouse and rat.
Blue Ice
+4°C
+4°C
Upon delivery aliquot
Avoid freeze / thaw cycle, Store in the dark
This conjugated primary antibody is “made to order” and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link® conjugation technology, Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
This product is FOR RESEARCH USE ONLY. For commercial use, please contact partnerships@abcam.com.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This supplementary information is collated from multiple sources and compiled automatically.
CD7 also known as Leu-9 or GP40 is a cell surface protein with a mass of approximately 40 kDa. The target is mainly expressed on T cells and NK cells and can be found during early T-cell development. Researchers also report CD7 expression in some B cell lineage progenitors. The CD7 function involves mediating cell signal transduction which contributes to the activation and differentiation of immune cells making it an important target in immunology studies.
CD7 plays a role in modulating interactions between immune cells without being part of a larger complex. It bridges interactions promoting immune responses by influencing T cell proliferation and cytokine production. CD7 control is important in regulating immune response intensity and provides an essential checkpoint in immune system modulation. Variations in CD7 function can significantly influence immune cell behavior impacting host defense mechanisms.
CD7 participates in immune signaling pathways such as the T-cell receptor (TCR) signaling pathway. This pathway is essential for T cell activation and involves proteins like CD3 and ZAP-70 which work together with CD7 to transduce activation signals. Alterations in the CD7 pathway can affect the downstream signaling events leading to changes in immune cell activation and function.
Aberrations in CD7 expression or function link to conditions like T-cell acute lymphoblastic leukemia (T-ALL) and certain autoimmune diseases. In T-ALL abnormal CD7 expression serves as an indicator for diagnosis and disease progression monitoring. CD7 also interacts with proteins such as CD45 and CD3 which play roles in leukemogenesis and immune system dysregulation. Studies also explore anti-CD7 strategies for therapeutic interventions aiming to modulate its activity for treating these conditions effectively.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com